Clinical Trials Directory

Trials / Completed

CompletedNCT00821977

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
338 (actual)
Sponsor
Novartis · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.

Conditions

Interventions

TypeNameDescription
DRUGVildagliptin
DRUGVildagliptin
DRUGPlacebo

Timeline

Start date
2008-11-01
Primary completion
2010-10-01
Completion
2010-10-01
First posted
2009-01-14
Last updated
2020-12-17

Locations

176 sites across 8 countries: United States, Canada, India, Malaysia, Philippines, Puerto Rico, Romania, Slovakia

Source: ClinicalTrials.gov record NCT00821977. Inclusion in this directory is not an endorsement.

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes (NCT00821977) · Clinical Trials Directory